TY - JOUR
T1 - Decade in review--dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemia
AU - Kastelein, John J. P.
PY - 2014
Y1 - 2014
N2 - Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future
AB - Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future
U2 - https://doi.org/10.1038/nrcardio.2014.132
DO - https://doi.org/10.1038/nrcardio.2014.132
M3 - Editorial
C2 - 25200284
SN - 1759-5002
VL - 11
SP - 629
EP - 631
JO - Nature Reviews. Cardiology
JF - Nature Reviews. Cardiology
IS - 11
ER -